Published in final edited form as:

Immunol Allergy Clin North Am. 2007 August ; 27(3): 457–475.

Cardiovascular Manifestations of Hypereosinophilic Syndromes

Princess Ogbogu, M.D.^a,

Clinical Fellow, Allergy and Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health

Douglas R. Rosing, M.D.^b, and

Staff Clinician, Cardiology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health

McDonald K. Horne III, M.D.^c

Senior Clinical Investigator, Hematology Service, Department of Laboratory Medicine, W. G. Magnuson Clinical Center

Background

The hypereosinophilic syndromes (HES) are characterized by persistent marked eosinophilia (>1500 eosinophils/mm³), the absence of a primary cause of eosinophilia (such as parasitic or allergic disease), and evidence of eosinophil-mediated end organ damage [1]. Cardiovascular complications of HES are a major source of morbidity and mortality in these disorders. Whereas earlier studies reported that up to 84% of HES patients have signs and symptoms of cardiac disease, more recent reports suggest that the frequency is closer to 40-50% [1-3].

The most characteristic cardiovascular abnormality in HES is endomyocardial fibrosis, initially described in 1936 by Loeffler, who called it “fibroplastic parietal endocarditis with blood eosinophilia.” Patients with HES may also develop thrombosis, particularly in the cardiac ventricles, but also occasionally in deep veins. Because of the rarity of these disorders, specific guidelines for the management of the cardiac and thrombotic complications of HES are lacking. In this chapter, we review the diagnosis and management of the cardiovascular manifestations of HES.

Differential Diagnosis

The differential diagnosis of cardiac disease with peripheral eosinophilia includes HES, Churg-Strauss syndrome (CSS), early giant-cell myocarditis, hypersensitivity reactions (usually medication induced), parasitic infection [4], Loeffler’s or tropical endomyocardial fibrosis (TEF), and malignancy [5]. Although there is considerable overlap in the cardiac manifestations of HES with other entities listed above, some distinguishing features do exist. For example, TEF and HES are almost identical in presentation, except that TEF occurs in long-term residents of tropical or subtropical regions and is likely, at least in some cases, secondary to the eosinophilia of helminth infection [6]. An appropriate travel history in a patient

^aCorresponding author for proof and reprints: Princess Ogbogu, M.D., Room B1-05, Bldg 4, NIH, Bethesda, MD 20892, ogbogup@niaid.nih.gov, (301)451-1889, (301) 480-3757 (fax)

^bCoauthor address: Douglas R. Rosing, M.D., Room 5-3330, CRC, Bldg 10, NIH, Bethesda, MD 20892, rosingd@nhlbi.nih.gov, (301) 451-8018

^cCoauthor address: McDonald K. Horne, III, M.D., Room 2C306, Bldg 10, NIH, Bethesda, MD 20892, mhorne@cc.nih.gov (301) 496-6891

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

with endomyocardial fibrosis and peripheral eosinophilia should, therefore, prompt an evaluation for helminth infection. Similarly, cardiovascular involvement in CSS includes many of the common manifestations of HES, such as eosinophilic endomyocarditis, congestive heart failure, and valvular disease. Other manifestations, such as coronary arteritis, sometimes resulting in myocardial infarction or sudden death, and pericarditis are highly suggestive of CSS [7-9].

Cardiac Pathology

The cardiac pathology of HES has traditionally been divided into three stages: acute necrosis, thrombosis, and fibrosis [10,11]. Previous studies indicate that the acute necrotic stage is observed when the duration of illness is short (mean duration 5.5 weeks), while the thrombotic stage occurs when the mean duration of eosinophilia is 10 months. The third, late fibrotic stage is described after approximately 24.5 months of disease duration[11].

The acute necrotic stage is characterized by eosinophilic infiltration of the myocardium associated with myocardial necrosis due to release of toxic cationic proteins from degranulating eosinophils [12,13]. In one series, patients were noted to have prominent splinter hemorrhages during the necrotic stage [11]. However, it is often difficult to diagnose cardiac disease at this stage as the patient may not have cardiac symptoms, and electrocardiography and echocardiography are often unremarkable. Endomyocardial biopsy may be required for diagnosis at this stage, although cardiac magnetic resonance (CMR) imaging may be useful in demonstrating preclinical involvement.

The acute myonecrosis is followed by formation of mural thrombi, often involving both ventricles, the ventricular outflow tracts, and the subvalvular regions. This process may lead to atrioventricular valvular incompetence [14]. In patients with HES, the most obvious stimulus for thrombosis is ventricular wall vascular damage. Disruption of the normally anticoagulant endothelial lining exposes von Willebrand factor (vWf), collagen, and tissue factor (TF). vWf and collagen bind platelets, and TF binds activated factor VII (fVIIa) to start the biochemical reactions that generate a fibrin thrombus [15,16]. In HES, the stimulation of fibrin formation by TF may be especially important since eosinophils contain TF in their specific granules, and they can induce endothelium to express it [17,18]. Secreted eosinophil proteins may also impair the anticoagulant properties of the endothelial membrane by binding to thrombomodulin [19]. There is some evidence that eosinophil granule proteins can activate factor XII and platelets and that mononuclear cells from patients with HES have enhanced procoagulant activity [20-22]. Therefore, blood hypercoagulability may also contribute to the pathogenesis of thrombosis in HES. In the cardiac chambers, flow at the endomyocardial surface is relatively static, particularly in the ventricular apices, and becomes more static in areas of hypokinesis. Stasis is a major stimulus for thrombosis because it allows activated clotting factors to accumulate to thrombotic concentrations.

Thrombus formed on denuded myocardium is replaced by fibrosis (Fig 1). Patients with HES may not be diagnosed with cardiac involvement until this final pathologic stage of their disease, when they present with scarring of the chordae tendinae and endocardium leading to a restrictive or dilated cardiomyopathy as well as progressive valvular incompetence [23]. The valvular pathology most commonly observed in HES includes dysfunctional, regurgitant atrioventricular valves due to restriction of valve leaflet mobility. Aortic and mitral stenosis have been reported much less commonly [24].

Clinical Manifestations of Cardiac Pathology

Clinical evidence of cardiac involvement in HES includes signs and symptoms of heart failure, intracardiac thrombus, myocardial ischemia, arrhythmias, and rarely pericarditis [3,25]. In an

early review of 65 cases of HES in the English literature, the most common presenting symptom was dyspnea, occurring in 60% of the patients. Seventy-five percent of the 55 patients who could be evaluated had signs and symptoms of congestive heart failure and 4% had evidence of pericarditis [3]. In the same review of 26 HES patients followed prospectively at the NIH, 42% had dyspnea, 27% had chest pain, 12% had cough, 8% had palpitations, and 4% had embolic events [3]. These patients were subsequently found to have mitral regurgitation (42%), congestive heart failure (38%), aortic regurgitation (4%), and aortic stenosis (4%). Myocardial infarction is a rarely reported complication of HES, but has been described to occur as the result of an embolic event due to endomyocardial fibrosis and thrombus in the left ventricular outflow tract [26].

Early descriptions of risk factors for cardiac disease in HES patients included male sex, HLA-Bw44 positivity, splenomegaly, thrombocytopenia, elevated serum vitamin B12, dysplastic eosinophils (hypogranular or vacuolated), and the presence of abnormal early myeloid precursors [11]. More recently, it has become apparent that these features are characteristic of a myeloproliferative variant of HES that includes chronic eosinophilic leukemia (CEL) associated with the *FIP1L1-PDGFR* (FP) fusion tyrosine kinase [27].

Diagnosis of HES-Associated Heart Disease

The most frequently used modalities to evaluate cardiac disease in HES include electrocardiography, echocardiography, CMR imaging, and endomyocardial biopsy. The most common electrocardiogram findings in HES are nonspecific and include T wave inversions, left atrial enlargement, left ventricular hypertrophy, incomplete right bundle branch block, and left axis deviation [3]. Other reported electrocardiogram abnormalities include ventricular premature complexes, poor R wave progression, nonspecific S-T and T wave abnormalities, and first degree atrioventricular block [3]. There is a single case report of an HES patient presenting with second degree atrioventricular block [28]. In general, electrocardiography is a screening tool that detects changes related to the underlying cardiac pathology in HES, especially left ventricular hypertrophy, but does not reveal any abnormalities that are specific for HES.

Echocardiography has long been a useful non-invasive diagnostic tool in the evaluation of cardiac disease in HES. The traditional modality for cardiac evaluation is two-dimensional echocardiography. Recent reports suggest that transthoracic, transesophageal, and contrast echocardiography play complementary roles in the evaluation of HES. Contrast echocardiography allows for delineation of the left ventricular shape and quantitation of left ventricular hypertrophy [29]. The classic echocardiographic findings in HES include endomyocardial thickening, left and right ventricular apical thrombus formation, and posterior mitral leaflet involvement [2] (Fig 2). There are often progressive features of a restrictive cardiomyopathy with regurgitation of the atrioventricular valves secondary to subvalvular damage [14]. Doppler indices of left ventricular compliance should be evaluated and can be used to follow the severity of the restrictive process. In an NIH study of 22 HES patients, 68% showed echocardiographic features of left ventricular free wall thickening, 37% showed an increase in left atrial transverse dimension, and 27% showed an increase in right ventricular transverse dimension [3]. Unsuspected pericardial effusions were found by echocardiography in 32% of these patients [3]. In a Mayo Clinic series of 51 patients with HES, 49% had cardiac disease by echocardiography. This group with echocardiographic evidence of HES also had higher rates of embolization, clinical heart failure, and cardiac surgery [2].

In recent years, CMR imaging has emerged as a highly useful non-invasive modality for the diagnosis of cardiac involvement in HES. CMR imaging is more sensitive to and specific for the detection of ventricular thrombi than either transthoracic or transesophageal

echocardiography [30] (Fig 3). Delayed enhancement gadolinium imaging is capable of detecting myocardial fibrosis and inflammation [31] (Fig 4). CMR imaging uses inversion-recovery prepared T1-weighted gradient-echo sequencing after the intravenous administration of gadolinium chelate to demonstrate nonviable tissue as delayed enhancement [32]. Delayed enhancement resulting from fibrosis is more intense than delayed enhancement due to inflammation [30]. There are several recent case reports describing CMR imaging as an adjunct diagnostic modality in HES [23,30,32,33]. One report describes the use of cine-MRI to aid in right ventricular endomyocardectomy in an HES patient [34].

Despite steadily improving non-invasive methods to aid in the diagnosis of HES, endomyocardial biopsy remains the diagnostic gold standard (Fig 5). Currently serial myocardial biopsies are used to provide information on the clinical course of cardiac disease and the response to treatment. The histopathologic features of HES endomyocardial diseases include fibrotic thickening of the endocardium, mural thrombosis, and fibrinoid change, thrombosis, and inflammation of the small intramural coronary vessels. Lastly, infiltration of eosinophils into the myocardium and sometimes endocardium may also be detected [10]. Although endomyocardial biopsy is the gold standard, the high resolution of CMR imaging permits tissue characterization which makes this technique a promising, and perhaps, more practical method to follow and potentially diagnose cardiac disease in HES.

Management of HES Heart Disease

The initial approach to the cardiac evaluation of a patient with HES includes a good history and a thorough physical exam looking for evidence of cardiovascular involvement, particularly cardiac decompensation or peripheral thromboembolic events. A baseline electrocardiogram, two-dimensional echocardiogram, and chest x-ray should be obtained. As previously mentioned, the common findings on electrocardiogram are generally nonspecific and include nonspecific S-T and T wave abnormalities, and in later stages evidence of left ventricular hypertrophy. Two-dimensional echocardiography with Doppler flow measurements is essential to evaluate the degree of ventricular hypertrophy, the presence of valvular abnormalities, the presence of mural or apical thrombi, and to estimate ventricular systolic and diastolic function. If initial transthoracic echocardiography is normal, it should be repeated at a minimum of 6-month intervals. If evidence of cardiac disease is found, more frequent echocardiograms may be warranted. The electrocardiogram should be repeated at a similar frequency. If there is evidence of endocardial thickening or difficulty obtaining optimal images, transesophageal echocardiography and/or CMR imaging should be performed. If a question of disease involvement or severity still remains, a cardiac biopsy is necessary.

All patients who have evidence of MHES or cardiac involvement should be screened by FISH or PCR for the *FIP1L1-PDGfra* (FP) mutation since the tyrosine kinase inhibitor, imatinib, is the treatment of choice for patients with this mutation. Although imatinib therapy is associated with clinical, hematologic and molecular remission in most patients with FP-associated CEL, signs and symptoms of congestive heart failure in patients with endomyocardial fibrosis remain unaffected in the majority of cases [35]. This is likely due to the presence of irreversible structural damage as a result of chronic fibrosis and emphasizes the need for prompt treatment with imatinib in these patients. It is recommended that screening be performed with a baseline serum troponin T level prior to the initiation of imatinib therapy. Pretreatment with steroids should be initiated before imatinib therapy if the baseline serum troponin T level is elevated or there is evidence of active cardiac disease, as imatinib may be associated with an acute drug-induced cardiomyopathy with resultant clinical decompensation [36-38]. There have been case reports of cardiac toxicity associated with long-term imatinib therapy, though larger clinical databases have not shown similar findings [39,40].

Symptoms of congestive heart failure should be managed with conventional medications including diuretics, beta-adrenergic blockers, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), aldosterone antagonists and digoxin [41]. Control of concomitant co-morbid conditions such as cardiac dysrhythmias, diabetes mellitus, thyroid dysfunction, anemia, and hypertension should be optimized. Most patients with clinically significant atrioventricular valvular regurgitation no longer need to use prophylactic antibiotic treatment prior to dental and surgical procedures according to the new American Heart Association guidelines. However, if the patient has a prosthetic heart valve, a history of previous infective endocarditis or certain congenital heart disorders, antibiotic prophylaxis is still recommended [42].

Surgical intervention secondary to progressive valvular dysfunction may become necessary. The experience with valve replacement in HES patients is very limited due to the rarity of the disease. However, valve replacement and, less frequently, valve repair in HES patients have been described [43,44]. Damaged valves can be replaced with mechanical or bioprosthetic valves. Despite anticoagulation, mechanical valve replacement may have a high incidence of thrombosis, while bioprosthetic valves may require more frequent replacement due to deterioration. In 1991, Boustany reported a collection of eight cases of mitral valve operations for HES [43]. Since then, 6 other reports have been published [45]. Mitral valve replacement is the most common surgery performed, although one case of mitral valve annuloplasty for HES has been reported [46]. The use of mechanical valves in this patient group incurs a high risk of thrombosis despite the use of anticoagulation [47]. In the limited number of patients reported with mechanical valve obstructive thrombosis, reoperation was associated with high mortality [44,47]. Obstruction of mechanical valves may occur rapidly, and in some cases has been reported to develop within days to months of surgery despite anticoagulant therapy [48]. Repeat surgery often leads to replacement of the mechanical valve with a bioprosthetic valve.

Because of these considerations, the use of bioprosthetic valves has been advocated, despite the frequent young ages of the patients and apprehension about early valve deterioration. The restrictive cardiomyopathy associated with a small left ventricular cavity is an additional concern and favors the use of a low profile valve [45]. Interestingly, a report of a young boy with HES requiring several mitral valve operations described recurrent thrombotic events despite the use of a bioprosthetic valve and documented therapeutic anticoagulation [48]. Because of these concerns, a heterograft bioprosthesis should be used in conjunction with warfarin therapy. It is also highly recommended that the peripheral eosinophilia be controlled prior to valve replacement or repair. It should be noted that the majority of the case reports of repeat valve thrombosis were prior to the use of imatinib treatment and may reflect the effects of persistent uncontrolled eosinophilia.

If the restrictive cardiomyopathy progresses and/or recurrent valve thrombosis occurs, heart transplantation should be considered. The use of orthotopic heart transplant has been described in only three patients with HES. All patients are reported to be alive (ISHLT Registry 2005) [49]. In the most recent case, a 50-year old man with HES received an orthotopic heart transplant, and despite treatment with tacrolimus and prednisone, required reintroduction of hydroxyurea treatment five weeks after transplant due to uncontrolled eosinophilia. The patient was subsequently shown to be FP mutation positive and was started on imatinib, which led to resolution of the eosinophilia [49]. After cardiac transplant, graft rejection must be monitored by serial endomyocardial biopsies, which are useful in assessing the degree of eosinophil graft infiltration. As is the case with valve replacement or repair, peripheral eosinophilia should be controlled before heart transplantation is considered.

Thrombotic Complications of HES

Descriptions of thromboembolism in HES patients have largely been published in successive literature reviews, each contributing a few more patients [1,3,50-52]. Isolated cases of intra-abdominal, cerebral, and cutaneous thrombosis have also been reported. Some of these had cardioembolic disease involving multiple organs, and occasionally the origin of the thrombi appeared to be multifocal [53-57]. In many cases, a causal link between eosinophilia and the thrombotic event was unclear, though in a few instances eosinophilic infiltrates were documented in involved tissues [58-69]. In some, additional predispositions to thrombosis were present, such as immobility, genetic hypercoagulability, or advanced atherosclerosis [70-72].

The best described thromboembolic events and those most clearly related to eosinophilia are the cases of intracardiac thrombus and secondary pulmonary and arterial emboli. In 1975, Chusid, et al. collected 57 cases of “broadly defined” HES from the English literature and added 14 of their own seen at the NIH [1]. Four of these 14 had arterial emboli (29%); one patient (7%) died of thromboembolic complications. Autopsies performed on 39 of the previously reported cases revealed cardiac mural thrombi in 16 (41%). However, among the 31 cases with a stated cause of death, only 2 (7%) were reported to have died of embolic disease. Fifteen per cent of the autopsied cases had “myocardial necrosis associated with thrombi in the smaller coronary vessels,” which presumably contributed to the demise of the 20 of 31 patients who died of myocardial infarction and congestive heart failure. The relationship of the coronary thrombi to the patients’ eosinophilia is unclear. They could have resulted from coincidental atherosclerotic disease or from local eosinophilic infiltrates. The left ventricle more often contained thrombus than the right, and clot tended to be located in the apices of the ventricles, where stasis is more of a factor, rather than in the outflow tracts. Splenic infarcts were also commonly discovered at autopsy. Pulmonary emboli were relatively rare. Microthrombi were sometimes found in cerebral vessels and microemboli in renal vessels.

In 1979, the NIH investigators reviewed 65 cases of HES, including 26 previously unpublished cases of their own. Only one (4%) of the 26 new cases had had an embolic clinical event [3, 50]. At autopsy, this patient did not have intracardiac thrombi, but he had been taking warfarin. One other case had undergone a post mortem exam, which revealed extensive thrombus in the left ventricle overlying endocardial fibrosis. A third patient developed portal vein thrombosis. Subsequently 8 out of 50 NIH patients were reported to have had multiple emboli, and they were all in a subgroup of 21 patients with clinically overt heart disease (38% incidence) [73]. Six of 52 NIH patients had cerebral vascular accidents [51]. Five of these individuals had clinical heart disease secondary to HES.

In 1983, Spry, et al., in London reported 15 more patients, 10 of whom had had clinical thrombotic or embolic events (brain, spleen, kidneys, retina) with 3 dying of this complication [52]. At post mortem one of these had widespread arterial and venous thrombi, although no thrombi were found in the cardiac ventricles. The other 2 patients died with endomyocardial necrosis or fibrosis and cerebral infarcts, but apparently no demonstrable intracardiac thrombus.

The limited literature, therefore suggests that perhaps a quarter of HES patients develop thromboembolic complications and that 5-10% died of them. There is also the suggestion that thromboembolic disease associated with HES is particularly difficult to control. Among the NIH patients, 4 of 5 treated chronically with warfarin with “evidence of good patient compliance” developed recurrent emboli resulting in new neurologic deficits [51]. Among the 10 English patients with thrombotic or embolic complications, three developed these “while adequately anticoagulated with warfarin” [52]. In addition to these series, a few case reports promote the same impression. An 11-year old boy with eosinophilia and cerebral sinus

thrombosis died despite treatment with heparin [64]. A 65 year old Japanese woman with idiopathic hypereosinophilia died 3 months after surgical removal of a large left ventricular thrombus, despite anticoagulation with warfarin [74]. A 26-year old man who had mitral and tricuspid valve prostheses because of HES-related endocarditis suffered a cerebral embolus despite taking warfarin and demonstrated apparent heparin resistance during subsequent cardiopulmonary bypass [75].

Although these reports suggest a pessimistic prognosis for hypereosinophilic patients with thrombosis, they describe a relatively small number of patients, and they give little quantitative data about their level of anticoagulation. Most of the patients on warfarin were monitored with the prothrombin time (PT) rather than the international normalized ratio (INR), which is a more reproducible measurement. In some instances, the patients were clearly under anticoagulated by today's standards. The goal of anticoagulation for the aforementioned 26-year old patient, for example, was a PT of only 16.5s, and his resistance to heparin may have represented heparin-induced thrombocytopenia [75]. Therefore, it is difficult to judge how refractory these patients would have been to anticoagulation administered according to current guidelines.

Management of Thrombotic Complications of HES

In the complete absence of information about whether anticoagulation could prevent the progression of HES cardiac disease from the thrombotic to the fibrotic stage, prophylactic treatment for this indication cannot be recommended. However, HES patients with evidence of intracardiac thrombosis by echocardiography or CMR imaging should be treated with anticoagulant therapy because of reports, limited though they are, that ~25% of these patients develop emboli [1,51,52]. On the basis of the published experience with intracardiac thrombosis associated with HES and the much larger experience following myocardial infarction, it is likely that anticoagulation that conforms to the current recommendations for treating thromboembolic disease in other patient populations can significantly reduce, if not eliminate, the risk of emboli in patients with HES.

A meta-analysis in 1993, for example, concluded that anticoagulation with heparin, but not antiplatelet therapy, can prevent the formation of echocardiographically demonstrated thrombi after myocardial infarction and reduce the risk of embolization [76]. Preventing thrombi is more difficult than preventing emboli, but emboli are the chief source of morbidity. Twenty-two to 56% of patients receiving ≤ 1000 units/hour of unfractionated heparin were reported to develop mural thrombi within 11 days after myocardial infarction, but only 0 - 10% of these patients developed clinically apparent emboli [77-82]. Heparin doses exceeding 1000 units/hour were more effective. In 1999, a meta-analysis of 31 trials found that the frequency of strokes after myocardial infarction was reduced by 63% in patients who took warfarin with a target INR of 3-5 and by 53% in those with an INR of 2-3 [83]. In more recent studies, both warfarin with an INR of 2.8 - 4.2 and warfarin with an INR of 2-2.5 in combination with 75 mg/d aspirin were shown to be equally protective against strokes and significantly more protective than 160 mg/d of aspirin alone [84]. In another study, a slightly lower INR (1.5 - 2.5) in combination with 81 mg/d aspirin provided the same level of protection as 162 mg/d aspirin alone [85]. On the basis of these studies, therefore, the threshold INR to prevent cardioemboli appears to be ~ 3.0 , although similar results may be achievable with an INR of 2 - 3 supplemented with aspirin. Treatment of thrombosis should begin with an agent that will damp the prothrombotic mechanisms quickly. For arterial thrombosis this means aspirin, with or without a form of heparin, and for venous thrombosis, a form of heparin [86,87]. In a patient who has active thrombosis, warfarin should not be given until heparin is started since warfarin will not induce therapeutic anticoagulation for several days. If warfarin is given alone, it may even transiently increase coagulability [88,89].

In most patients, the parenteral anticoagulant of choice is a low molecular weight (LMW) heparin because this drug usually requires no monitoring and can be administered to outpatients [90]. Several LMW heparins are marketed. They are very similar in efficacy and price. Enoxaparin (Lovenox), dalteparin (Fragmin), and tinzaparin (Innohep) are the most commonly prescribed in the U.S. and are given subcutaneously every 12 or 24 hours. Because these drugs are excreted by the kidney, they should be used with caution in patients with renal insufficiency. There is more information about the excretion of enoxaparin than the other LMW heparins. It appears that enoxaparin can be safely administered with creatinine clearances as low as 30 mL/minute[91]. The dose is weight-based even in obese patients, although somewhat higher doses of LMW heparin may be required for patients in critical care settings [91,92].

Unlike unfractionated heparin, LMW heparin has minimal if any effect on the aPTT because its anticoagulant activity comes largely from its inhibition of activated factor X (fXa) rather than thrombin. However, if LMW heparin does need monitoring, for example in a patient with marginal renal function, this is possible with an assay that specifically measures anti-fXa activity in units/mL. Blood for the test should be drawn ~4 hours after a subcutaneous dose. Therapeutic anti-fXa levels at that point are 0.5 - 1.2 IU/mL.

Unfractionated heparin is advisable for patients at high risk of bleeding or who are critically ill because its anticoagulant activity can be completely reversed with protamine and it is only partially dependent upon renal excretion [90]. Although dosing recommendations vary, a commonly used regimen for venous thrombosis is an intravenous bolus of 80 u/kg followed by 18 u/kg/hr by continuous infusion [90]. Traditionally the dose has been adjusted 6 hours later to prolong the activated partial thromboplastin time (aPTT) 1.5-2.5 times the "control" value. However, this practice often results in subtherapeutic anticoagulation because the sensitivity of the aPTT to heparin varies with different reagents [90]. Also the meaning of "control" is often unclear. Currently, it is recommended that each laboratory establish a therapeutic range of aPTT for heparin based upon calibrations with known amounts of heparin. No therapeutic range is appropriate, however, if the patient's pre-treatment aPTT is abnormal. Lupus anticoagulants, which are not rare, can elevate the aPTT to make it especially sensitive to heparin. Such patients will be significantly under anticoagulated if the aPTT is used to adjust their dose of heparin. Anticoagulation in these patients should be monitored with the anti-fXa assay (therapeutic range, 0.3 - 0.7 IU/mL, different from that for LMW heparin).

Warfarin should be begun simultaneously with heparin or soon thereafter. Heparin must be continued for at least 5 days and until warfarin has achieved a stable INR between 2 and 3. The transition from heparin to warfarin should not be hurried since unstable anticoagulation at this early stage risks treatment failure.

The downside to antithrombotic treatment, of course, is the risk of bleeding. It has been estimated that 4% - 6% of patients treated with standard or low molecular weight heparin for acute deep vein thrombosis develop major bleeding [93-95]. The risk increases with the dose of anticoagulant and with the presence of co-morbid conditions. About 5% of patients taking warfarin have a major bleed each year [84,96-98]. However, the risk of bleeding on warfarin is greatest during the first 3 months of treatment, increases with co-morbidities, and rises sharply at INRs >4.5 [95,96,99]. In a study with over 12,500 patients the annual risk of major bleeding from antithrombotic doses of aspirin (≤ 325 mg/d) was 2.7% [100]. Combining 100 mg/d of aspirin with warfarin at an INR of 3.0-4.5 increased the annual risk of major bleeding in patients with artificial heart valves from 10% to 13% [101]. The clinical challenge, therefore, is to balance these bleeding risks with the potential benefits of administering antithrombotic agents.

HES patients can have thromboembolic events unrelated to or only partially related to their hypereosinophilia [70-72]. Therefore, in deciding about the duration of anticoagulation, consideration must be given to whether the initial clinical event followed surgery or occurred during hospitalization or another period of relative immobility [102]. However, testing a patient for genetic predispositions (e.g., factor V Leiden, prothrombin G20210A) to thrombosis rarely impacts the decision about the duration of anticoagulation [103].

The recommended duration of anticoagulation is based upon the assumption that the risk of recurrent thrombosis and/or embolism is high until or unless the inciting cause(s) is eliminated. Therefore, in patients with HES, the duration of anticoagulation should be determined by the activity of the patient's endomyocardial disease. If this is controlled and if echocardiography reveals the absence of thrombus or resolution of thrombus, it is reasonable to discontinue anticoagulation. The balance between the risks and benefits of anticoagulation, however, must be continuously reassessed.

Conclusions

Cardiovascular manifestations of the hypereosinophilic syndrome are a common cause of morbidity and mortality in an otherwise uncommon disorder. The management of cardiovascular disorders in HES includes normalization of the peripheral eosinophil count, screening for the *FIP1L1-PDGfra* mutation and treating with imatinib if present, optimizing cardiac function by medical and surgical intervention, initiating anticoagulant therapy in patients with or at risk for thrombotic complications, and considering heart transplantation for patients with progressive cardiac disease despite conventional management.

Acknowledgements

This work was supported by intramural research funding from NIH/NIAID, and the W.G. Magnuson Clinical Center.

References

- [1]. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. *Medicine (Baltimore)* Jan;1975 54(1):1-27. [PubMed: 1090795]
- [2]. Ommen SR, Seward JB, Tajik AJ. Clinical and echocardiographic features of hypereosinophilic syndromes. *Am J Cardiol* Jul 1;2000 86(1):110-113. [PubMed: 10867107]
- [3]. Parrillo JE, Borer JS, Henry WL, Wolff SM, Fauci AS. The cardiovascular manifestations of the hypereosinophilic syndrome. Prospective study of 26 patients, with review of the literature. *Am J Med* Oct;1979 67(4):572-582. [PubMed: 495628]
- [4]. Ginsberg F, Parrillo JE. Eosinophilic myocarditis. *Heart Fail Clin* Oct;2005 1(3):419-429. [PubMed: 17386864]
- [5]. Cooper LT, Zehr KJ. Biventricular assist device placement and immunosuppression as therapy for necrotizing eosinophilic myocarditis. *Nat Clin Pract Cardiovasc Med* Oct;2005 2(10):544-548. [PubMed: 16186853]
- [6]. Nutman TB, Miller KD, Mulligan M, Ottesen EA. Loa loa infection in temporary residents of endemic regions: recognition of a hyperresponsive syndrome with characteristic clinical manifestations. *J Infect Dis* Jul;1986 154(1):10-18. [PubMed: 3458832]
- [7]. Hasley PB, Follansbee WP, Coulehan JL. Cardiac manifestations of Churg-Strauss syndrome: report of a case and review of the literature. *Am Heart J* Oct;1990 120(4):996-999. [PubMed: 2220558]
- [8]. Pela G, Tirabassi G, Pattoneri P, Pavone L, Garini G, Bruschi G. Cardiac involvement in the Churg-Strauss syndrome. *Am J Cardiol* May 15;2006 97(10):1519-1524. [PubMed: 16679097]
- [9]. Noth I, Streck ME, Leff AR. Churg-Strauss syndrome. *Lancet* Feb 15;2003 361(9357):587-594. [PubMed: 12598156]

- [10]. Fauci AS, Harley JB, Roberts WC, Ferrans VJ, Gralnick HR, Bjornson BH. NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. *Ann Intern Med* Jul;1982 97(1):78–92. [PubMed: 7046556]
- [11]. Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. *Blood* May 15;1994 83(10):2759–2779. [PubMed: 8180373]
- [12]. Young JD, Peterson CG, Venge P, Cohn ZA. Mechanism of membrane damage mediated by human eosinophil cationic protein. *Nature* Jun 5-11;1986 321(6070):613–616. [PubMed: 2423882]
- [13]. Tai PC, Ackerman SJ, Spry CJ, Dunnette S, Olsen EG, Gleich GJ. Deposits of eosinophil granule proteins in cardiac tissues of patients with eosinophilic endomyocardial disease. *Lancet* Mar 21;1987 1(8534):643–647. [PubMed: 2882081]
- [14]. Zientek DM, King DL, Dewan SJ, Harford PH, Youman DJ, Hines TR. Hypereosinophilic syndrome with rapid progression of cardiac involvement and early echocardiographic abnormalities. *Am Heart J* Dec;1995 130(6):1295–1298. [PubMed: 7484788]
- [15]. Hoffman M, Monroe DM 3rd. A cell-based model of hemostasis. *Thromb Haemost* Jun;2001 85(6):958–965. [PubMed: 11434702]
- [16]. Ruggeri ZM. Platelet interactions with vessel wall components during thrombogenesis. *Blood Cells Mol Dis* Mar-Apr;2006 36(2):145–147. [PubMed: 16469513]
- [17]. Wang JG, Mahmud SA, Thompson JA, Geng JG, Key NS, Slungaard A. The principal eosinophil peroxidase product, HOSCN, is a uniquely potent phagocyte oxidant inducer of endothelial cell tissue factor activity: a potential mechanism for thrombosis in eosinophilic inflammatory states. *Blood* Jan 15;2006 107(2):558–565. [PubMed: 16166591]
- [18]. Moosbauer C, Morgenstern E, Cuvelier SL, et al. Eosinophils are a major intravascular location for tissue factor storage and exposure. *Blood* Feb 1;2007 109(3):995–1002. [PubMed: 17003379]
- [19]. Slungaard A, Vercellotti GM, Tran T, Gleich GJ, Key NS. Eosinophil cationic granule proteins impair thrombomodulin function. A potential mechanism for thromboembolism in hypereosinophilic heart disease. *J Clin Invest* Apr;1993 91(4):1721–1730. [PubMed: 8386194]
- [20]. Venge P, Dahl R, Hallgren R. Enhancement of factor XII dependent reactions by eosinophil cationic protein. *Thromb Res* 1979;14(45):641–649. [PubMed: 483259]
- [21]. Gambacorti Passerini C, Cortellaro M, Cofrancesco E, et al. Possible mechanisms of fibrin deposition in the hypereosinophilic syndrome. *Haemostasis* 1989;19(1):32–37. [PubMed: 2522075]
- [22]. Rohrbach MS, Wheatley CL, Slifman NR, Gleich GJ. Activation of platelets by eosinophil granule proteins. *J Exp Med* Oct 1;1990 172(4):1271–1274. [PubMed: 2212954]
- [23]. Salaniti GC. Endomyocardial fibrosis and intracardiac thrombus occurring in idiopathic hypereosinophilic syndrome. *AJR Am J Roentgenol* May;2005 184(5):1432–1433. [PubMed: 15855091]
- [24]. Hendren WG, Jones EL, Smith MD. Aortic and mitral valve replacement in idiopathic hypereosinophilic syndrome. *Ann Thorac Surg* Nov;1988 46(5):570–571. [PubMed: 3190333]
- [25]. Spiegel R, Miron D, Fink D, Gavriel H, Horovitz Y. Eosinophilic pericarditis: a rare complication of idiopathic hypereosinophilic syndrome in a child. *Pediatr Cardiol* Nov-Dec;2004 25(6):690–692. [PubMed: 14743307]
- [26]. D'Souza MG, Swistel DG, Castro JL, DeRose JJ Jr. Hypereosinophilic thrombus causing aortic stenosis and myocardial infarction. *Ann Thorac Surg* Nov;2003 76(5):1725–1726. [PubMed: 14602325]
- [27]. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. *N Engl J Med* Mar 27;2003 348(13):1201–1214. [PubMed: 12660384]
- [28]. Subhash HS, Asishkumar M, Jonathan M. Unusual cardiac manifestation of hypereosinophilic syndrome. *Postgrad Med J* Aug;2002 78(922):490–491. [PubMed: 12185226]
- [29]. Shah R, Ananthasubramaniam K. Evaluation of cardiac involvement in hypereosinophilic syndrome: complementary roles of transthoracic, transesophageal, and contrast echocardiography. *Echocardiography* Sep;2006 23(8):689–691. [PubMed: 16970721]
- [30]. Syed IS, Martinez MW, Feng DL, Glockner JF. Cardiac magnetic resonance imaging of eosinophilic endomyocardial disease. *Int J Cardiol*. Mar 29;2007

- [31]. Wagner A, Mahrholdt H, Holly TA, et al. Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study. *Lancet* Feb 1;2003 361(9355):374–379. [PubMed: 12573373]
- [32]. Plastiras SC, Economopoulos N, Kelekis NL, Tzelepis GE. Magnetic resonance imaging of the heart in a patient with hypereosinophilic syndrome. *Am J Med* Feb;2006 119(2):130–132. [PubMed: 16443414]
- [33]. Puvaneswary M, Joshua F, Ratnarajah S. Idiopathic hypereosinophilic syndrome: magnetic resonance imaging findings in endomyocardial fibrosis. *Australas Radiol* Nov;2001 45(4):524–527. [PubMed: 11903192]
- [34]. Chandra M, Pettigrew RI, Eley JW, Oshinski JN, Guyton RA. Cine-MRI-aided endomyocardectomy in idiopathic hypereosinophilic syndrome. *Ann Thorac Surg* Dec;1996 62(6):1856–1858. [PubMed: 8957409]
- [35]. Klion AD, Robyn J, Akin C, et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. *Blood* Jan 15;2004 103(2):473–478. [PubMed: 14504092]
- [36]. Klion AD, Bochner BS, Gleich GJ, et al. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. *J Allergy Clin Immunol* Jun;2006 117(6):1292–1302. [PubMed: 16750989]
- [37]. Pitini V, Arrigo C, Azzarello D. Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes. *Blood* 1 Nov 2003;102:934563457 author reply 3457 [PubMed: 14568908]
- [38]. Pardanani A, Reeder T, Porrata LF, et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. *Blood* May 1;2003 101(9):3391–3397. [PubMed: 12506022]
- [39]. Kerkela R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. *Nat Med* Aug;2006 12(8):908–916. [PubMed: 16862153]
- [40]. Hatfield A, Owen S. In reply to ‘Cardiotoxicity of the cancer therapeutic agent imatinib mesylate’. *Nat Med* Jan 2007;13:113 author reply 15–16 [PubMed: 17206118]
- [41]. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. *Circulation* Sep 20;2005 112(12):e154–235. [PubMed: 16160202]
- [42]. Wilson W, Taubert K, Gewitz M. Quality of Care and Outcomes Research Interdisciplinary Working Group. Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Circulation 19 Apr 2007
- [43]. Boustany CW Jr, Murphy GW, Hicks GL Jr. Mitral valve replacement in idiopathic hypereosinophilic syndrome. *Ann Thorac Surg* Jun;1991 51(6):1007–1009. [PubMed: 2039298]
- [44]. Fuzellier JF, Chapoutot L, Torossian PF. Mitral valve repair in idiopathic hypereosinophilic syndrome. *J Heart Valve Dis* May;2004 13(3):529–531. [PubMed: 15222304]
- [45]. Fuzellier JF, Chapoutot L, Torossian PF, Metz D, Baehrel B. Mitral valve replacement in idiopathic eosinophilic endocarditis without peripheral eosinophilia. *J Card Surg* Sep-Oct;2005 20(5):472–474. [PubMed: 16153283]
- [46]. Bell JA, Jenkins BS, Webb-Peploe MM. Clinical, haemodynamic, and angiographic findings in Löffler’s eosinophilic endocarditis. *Br Heart J* Jun;1976 38(6):541–548. [PubMed: 1275984]
- [47]. Watanabe K, Tournilhac O, Camilleri LF. Recurrent thrombosis of prosthetic mitral valve in idiopathic hypereosinophilic syndrome. *J Heart Valve Dis* May;2002 11(3):447–449. [PubMed: 12056741]
- [48]. Radford DJ, Garlick RB, Pohlner PG. Multiple valvar replacements for hypereosinophilic syndrome. *Cardiol Young* Jan;2002 12(1):67–70. [PubMed: 11922446]

- [49]. Korczyk D, Taylor G, McAlister H, et al. Heart transplantation in a patient with endomyocardial fibrosis due to hypereosinophilic syndrome. *Transplantation* Feb 27;2007 83(4):514–516. [PubMed: 17318086]
- [50]. Solley GO, Maldonado JE, Gleich GJ, et al. Endomyocardial pathy with eosinophilia. *Mayo Clin Proc* Nov;1976 51(11):697–708. [PubMed: 994551]
- [51]. Moore PM, Harley JB, Fauci AS. Neurologic dysfunction in the idiopathic hypereosinophilic syndrome. *Ann Intern Med* Jan;1985 102(1):109–114. [PubMed: 2981493]
- [52]. Spry CJ, Davies J, Tai PC, Olsen EG, Oakley CM, Goodwin JF. Clinical features of fifteen patients with the hypereosinophilic syndrome. *Q J Med* 1983;52(205):1–22. [PubMed: 6878618]
- [53]. Ishii T, Koide O, Hosoda Y, Takahashi R. Hypereosinophilic multiple thrombosis. A proposal of a new designation of disseminated eosinophilic “collagen disease”. *Angiology* Jun;1977 28(6):361–375. [PubMed: 869293]
- [54]. Ishii T, Sternby NH, Hosoda Y. Hypereosinophilic multiple thrombosis. *Vasa* 1978;7(3):303–308. [PubMed: 695880]
- [55]. Fitzpatrick JE, Johnson C, Simon P, Owenby J. Cutaneous microthrombi: a histologic clue to the diagnosis of hypereosinophilic syndrome. *Am J Dermatopathol* Oct;1987 9(5):419–422. [PubMed: 3688367]
- [56]. Kanno H, Ouchi N, Sato M, Wada T, Sawai T. Hypereosinophilia with systemic thrombophlebitis. *Hum Pathol* May;2005 36(5):585–589. [PubMed: 15948128]
- [57]. Funahashi S, Masaki I, Furuyama T. Hypereosinophilic syndrome accompanying gangrene of the toes with peripheral arterial occlusion--a case report. *Angiology* Mar-Apr;2006 57(2):231–234. [PubMed: 16518533]
- [58]. Elouaer-Blanc L, Zafrani ES, Farcet JP, Saint-Marc Girardin MF, Mathieu D, Dhumeaux D. Hepatic vein obstruction in idiopathic hypereosinophilic syndrome. *Arch Intern Med* Apr;1985 145(4):751–753. [PubMed: 3985740]
- [59]. Valente O, Scarpinella-Bueno MA. Deep venous thrombosis in hypereosinophilic syndrome. *Am Fam Physician* Oct;1994 50(5):921–922. [PubMed: 7942410]
- [60]. Kojima K, Sasaki T. Veno-occlusive disease in hypereosinophilic syndrome. *Intern Med* Dec;1995 34(12):1194–1197. [PubMed: 8929649]
- [61]. Mukai HY, Ninomiya H, Mitsuhashi S, Hasegawa Y, Nagasawa T, Abe T. Thromboembolism in a patient with transient eosinophilia. *Ann Hematol* Feb;1996 72(2):93–95. [PubMed: 8597615]
- [62]. Zylberberg H, Valla D, Viguie F, Casadevall N. Budd-Chiari syndrome associated with 5q deletion and hypereosinophilia. *J Clin Gastroenterol* Jul;1996 23(1):66–68. [PubMed: 8835906]
- [63]. Yamada T, Shinohara K, Katsuki K. A case of idiopathic hypereosinophilic syndrome complicated with disseminated intravascular coagulation. *Am J Hematol* Sep;1998 59(1):100–101. [PubMed: 9723589]
- [64]. Schulman H, Hertzog L, Zirkun H, Hertzanu Y. Cerebral sinovenous thrombosis in the idiopathic hypereosinophilic syndrome in childhood. *Pediatr Radiol* Aug 1999;29(8):595–597. [PubMed: 10415185]
- [65]. Kikuchi K, Minami K, Miyakawa H, Ishibashi M. Portal vein thrombosis in hypereosinophilic syndrome. *Am J Gastroenterol* May;2002 97(5):1274–1275. [PubMed: 12014753]
- [66]. Walker M. Idiopathic hypereosinophilia associated with hepatic vein thrombosis. *Arch Intern Med* Dec;1987 147(12):2220–2221. [PubMed: 3689079]
- [67]. Uemura K, Nakajima M, Yamauchi N, Fukayama M, Yoshida K. Sudden death of a patient with primary hypereosinophilia, colon tumours, and pulmonary emboli. *J Clin Pathol* May;2004 57(5):541–543. [PubMed: 15113865]
- [68]. Liapis H, Ho AK, Brown D, Mindel G, Gleich G. Thrombotic microangiopathy associated with the hypereosinophilic syndrome. *Kidney Int* May;2005 67(5):1806–1811. [PubMed: 15840027]
- [69]. Sakuta R, Tomita Y, Ohashi M, Nagai T, Murakami N. Idiopathic hypereosinophilic syndrome complicated by central sinovenous thrombosis. *Brain Dev* Apr;2007 29(3):182–184. [PubMed: 16996710]
- [70]. Narayan S, Ezughah F, Standen GR, Pawade J, Kennedy CT. Idiopathic hypereosinophilic syndrome associated with cutaneous infarction and deep venous thrombosis. *Br J Dermatol* Apr;2003 148(4):817–820. [PubMed: 12752146]

- [71]. Gumruk F, Gurgey A, Altay C. A case of hypereosinophilic syndrome associated with factor V Leiden mutation and thrombosis. *Br J Haematol* Apr;1998 101(1):208–209. [PubMed: 9576204]
- [72]. Johnston AM, Woodcock BE. Acute aortic thrombosis despite anticoagulant therapy in idiopathic hypereosinophilic syndrome. *J R Soc Med* Sep;1998 91(9):492–493. [PubMed: 9849524]
- [73]. Harley JB, Fauci AS, Gralnick HR. Noncardiovascular findings associated with heart disease in the idiopathic hypereosinophilic syndrome. *Am J Cardiol* Aug;1983 52(3):321–324. [PubMed: 6869280]
- [74]. Tanaka H, Kawai H, Tatsumi K, et al. Surgical treatment for Löffler's endocarditis with left ventricular thrombus and severe mitral regurgitation: a case report. *J Cardiol* Apr;2006 47(4):207–213. [PubMed: 16637255]
- [75]. Hanowell ST, Kim YD, Rattan V, MacNamara TE. Increased heparin requirement with hypereosinophilic syndrome. *Anesthesiology* Oct;1981 55(4):450–452. [PubMed: 7294380]
- [76]. Vaitkus PT, Barnathan ES. Embolic potential, prevention and management of mural thrombus complicating anterior myocardial infarction: a meta-analysis. *J Am Coll Cardiol* Oct;1993 22(4):1004–1009. [PubMed: 8409034]
- [77]. Friedman MJ, Carlson K, Marcus FI, Woolfenden JM. Clinical correlations in patients with acute myocardial infarction and left ventricular thrombus detected by two-dimensional echocardiography. *Am J Med* Jun;1982 72(6):894–898. [PubMed: 7091160]
- [78]. Visser CA, Kan G, Lie KI, Durrer D. Left ventricular thrombus following acute myocardial infarction: a prospective serial echocardiographic study of 96 patients. *Eur Heart J* May;1983 4(5):333–337. [PubMed: 6617680]
- [79]. Gueret P, Dubourg O, Ferrier A, Farcot JC, Rigaud M, Bourdarias JP. Effects of full-dose heparin anticoagulation on the development of left ventricular thrombosis in acute transmural myocardial infarction. *J Am Coll Cardiol* Aug;1986 8(2):419–426. [PubMed: 3734264]
- [80]. Davis MJ, Ireland MA. Effect of early anticoagulation on the frequency of left ventricular thrombi after anterior wall acute myocardial infarction. *Am J Cardiol* Jun 1;1986 57(15):1244–1247. [PubMed: 3717020]
- [81]. Turpie AG, Robinson JG, Doyle DJ, et al. Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. *N Engl J Med* Feb 9;1989 320(6):352–357. [PubMed: 2643772]
- [82]. Nihoyannopoulos P, Smith GC, Maseri A, Foale RA. The natural history of left ventricular thrombus in myocardial infarction: a rationale in support of masterly inactivity. *J Am Coll Cardiol* Oct;1989 14(4):903–911. [PubMed: 2794276]
- [83]. Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. *Jama* Dec 1;1999 282(21):2058–2067. [PubMed: 10591389]
- [84]. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. *N Engl J Med* Sep 26;2002 347(13):969–974. [PubMed: 12324552]
- [85]. Fiore LD, Ezekowitz MD, Brophy MT, Lu D, Sacco J, Peduzzi P. Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. *Circulation* Feb 5;2002 105(5):557–563. [PubMed: 11827919]
- [86]. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. *Lancet* May 31;1997 349(9065):1569–1581. [PubMed: 9174558]
- [87]. Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest* Sep;2004 126(3 Suppl):401S–428S. [PubMed: 15383479]
- [88]. Brandjes DP, Heijboer H, Buller HR, de Rijk M, Jagt H, ten Cate JW. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. *N Engl J Med* Nov 19;1992 327(21):1485–1489. [PubMed: 1406880]
- [89]. Deykin D. Warfarin therapy. 1. *N Engl J Med* Sep 24;1970 283(13):691–694. [PubMed: 4916914]
- [90]. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest* Sep;2004 126(3 Suppl):188S–203S. [PubMed: 15383472]

- [91]. Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. *Ann Intern Med* May 2;2006 144(9):673–684. [PubMed: 16670137]
- [92]. Priglinger U, Delle Karth G, Geppert A, et al. Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill? *Crit Care Med* May;2003 31(5):1405–1409. [PubMed: 12771610]
- [93]. Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. *Blood* Nov 1;1991 78(9):2337–2343. [PubMed: 1657248]
- [94]. Zidane M, Schram MT, Planken EW, et al. Frequency of major hemorrhage in patients treated with unfractionated intravenous heparin for deep venous thrombosis or pulmonary embolism: a study in routine clinical practice. *Arch Intern Med* Aug 14-28;2000 160(15):2369–2373. [PubMed: 10927736]
- [95]. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. *Am J Med* Sep;1993 95(3):315–328. [PubMed: 8368229]
- [96]. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy *Lancet* Aug;1996 348(9025):423–428.
- [97]. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. *Am J Med* Aug;1998 105(2):91–99. [PubMed: 9727814]
- [98]. Buresly K, Eisenberg MJ, Zhang X, Pilote L. Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction. *Arch Intern Med* Apr 11;2005 165(7):784–789. [PubMed: 15824298]
- [99]. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. *Ann Intern Med* Jun 1;1994 120(11):897–902. [PubMed: 8172435]
- [100]. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. *N Engl J Med* Aug 16;2001 345(7):494–502. [PubMed: 11519503]
- [101]. Turpie AG, Gent M, Laupacis A, et al. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. *N Engl J Med* Aug 19;1993 329(8):524–529. [PubMed: 8336751]
- [102]. Anderson FA Jr. Spencer FA. Risk factors for venous thromboembolism. *Circulation* Jun 17;2003 107(23 Suppl 1):I9–16. [PubMed: 12814980]
- [103]. Kearon C. Duration of therapy for acute venous thromboembolism. *Clin Chest Med* Mar;2003 24(1):63–72. [PubMed: 12685057]

Fig 1.

Fatal endomyocardial fibrosis in a patient with HES and FIP1L1/PGDFRA mutation. (From Stone RM, Gilliland DG, Klion AD. Platelet-derived growth factor receptor inhibition to treat idiopathic hypereosinophilic syndrome. *Semin Oncol.* Apr 2004;31(2 Suppl 6):12-17 with permission.)

Fig 2.

Echocardiogram of the same patient presented in Fig 1 . A) In the parasternal long axis view, an area of increased echo density (arrow) denotes thrombus and/or fibrosis along the basal posterior wall of the left ventricle which also involves the posterior leaflet of the mitral valve. B) Color Doppler in the same view demonstrates significant mitral regurgitation. C) In the short axis view shown during diastole, there is extensive thrombus and/or fibrosis on the posterior wall (arrow) with compromise of the left ventricular cavity size. (Courtesy of Dr. Vandana Sachdev, National Heart, Lung, and Blood Institute)

Fig 3.

Cine MRI in a 4-chamber view of the same patient presented in Fig. 1 using a steady-state free precession technique. Note that the right ventricular cavity is nearly obliterated.

Abbreviations: LV = left ventricle, RV = right ventricle, RA = right atrium, LA = left atrium. (Courtesy of Drs. Patricia Bandettini and Andrew Arai, National Heart, Lung, and Blood Institute)

Fig 4.

Delayed hyper-enhancement images of the same patient presented in Fig. 1 obtained 20 minutes after administration of gadolinium contrast using an inversion recovery gradient echo technique validated for imaging myocardial infarction. There is a bright white rim of enhancement lining the left ventricle (arrows) which is consistent with endomyocardial fibrosis. (Courtesy of Drs. Patricia Bandettini and Andrew Arai, National Heart, Lung, and Blood Institute)

Fig 5.
Histology of fatal endomyocardial fibrosis in the same patient presented in Fig. 1. Arrow denotes areas of intracardiac fibrosis bordered by areas of unaffected myocardium.